The standard 12-core prostate biopsy regimen is a 30-year old technology. It misses cancer in up to 30% of cases and results in the mischaracterization of tumors in 30-40% of positive biopsies.1 By failing to correctly identify the type of cancer within the prostate, more aggressive cancers may be missed and continue to grow unchecked. Furthermore, about half of those who seek treatment may not need it. The 3DBiopsy System is being created in response to the frustrations that physicians and patients experience with the current biopsy method. It is being designed to provide a complete, dimensional and systematic mapping of any cancerous lesion present in the prostate.